SAVA · Cassava Sciences, Inc.

Former Alzheimer's hopeful after failed Phase 3 trials

Risiko 10/10 · EXTREME RISK · broken biotech story · $— 🤖Von KI geschrieben

Kennzahlen

• Price —
• Market cap —
• P/E (ttm) —
• Div yield —
• 52-wk range —

Wichtigste Risiken

• No viable lead asset after simufilam's failures (Shareholders) — EXTREME
• Cash burned on a long-shot drug repurposing pivot (Shareholders) — EXTREME
• Legacy litigation and data-integrity fallout (Shareholders) — HIGH
• Fade into irrelevance if no second act materializes (Shareholders) — HIGH

Fazit

A speculation on a second act that may never come; the original thesis is gone.

Interaktive Analyse öffnen → Teilen

Recherche, keine Anlageberatung.